Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Results found: 3

first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Quality of life of patients after bariatric treatment – preliminary results

100%
Sierżantowicz R., Kirpsza B., Hady R., Trochimowicz L., Dadan J.
Progress in Health Sciences
|
2012
|
vol. 2
|
issue 1
89-94
EN
Introduction: Obesity afflicts approximately 3,000,000 people in Poland. Co-morbidities develop mainly in connection with morbid obesity. Bad health conditions connected with obesity may decrease the health-related quality of life (HRQOL). A body mass index of 30-34 kg/m2, along with co-morbidities, could be a reco-mmendation for surgical treatment. Reduction of body mass may cause recovery or symptoms relief. Bariatric surgery is currently the most effective method of morbid obesity treatment. Purpose: To evaluate the quality of life of patients after bariatric treatment. Materials and methods: Research material was gathered in the 1st Department of General and Endocrinological Surgery, University Hospital in Bialystok, by applying standardized BAROS among 108 patients after bariatric treatment. The study group included 73 women (67.6%) and 35 men (32.4%), between 20 and 60 years old (average age ± 40 years), and with a BMI of 41-52 (average BMI 45.5). Results: In 18 patients (16.6%) laparoscopic adjustable gastric banding (LAGB) was applied, in 58 (53.8%) sleeve gastrectomy was performed, and in 32 patients (29.6%) Roux-en-Y gastric bypass (RYGB) was applied. Significant difference (p<0. 0001) was stated in BMI according to the type of procedure. A higher reduction of BMI was obtained after RYGB than after LAGB and sleeve gastrectomy. Evaluation of quality of life was conducted six months after the surgery. No significant difference (p>0.05) was found in the quality of life depending on the surgery type. Complications that occurred after surgeries did not significantly influence the subjective evaluation of quality of life. Conclusions: The quality of life of the patients did not improve 6 months after bariatric surgery. This did not differ independently of weight loss in patients or of the type of surgery performed. Verifying obtained results after a longer period of time following the surgery is suggested
2

The presence of metastatic melanoma in the small intestine is associated with a poor prognosis - A Report of two cases

72%
Niewiarowska K., Pryczynicz A., Malla H., Łuba M., Dadan J., Kemona A., Niksa M., Famulski W.
Progress in Health Sciences
|
2013
|
vol. 3
|
issue 1
148-153
EN
Introduction: Malignant melanoma is a neoplasm arising from the melanocyte cells of the skin. Of all cancers diagnosed in Poland in 2009, it was the twelfth most-common cancer in men and the fourteenth in women. However, this type of cancer is characterized by a quick development of metastases and a high mortality rate. Melanoma usually metastasizes to the lymph nodes, then infiltrates the lungs, brain, liver, bones, and gastrointestinal tract, for example, the small intestine. Purpose: To present two cases of metastatic melanoma with a poor prognosis involving the small intestine. Case presentation: In the first case, a 50-year-old male patient with abdominal pain and distension was admitted to hospital and qualified for surgical treatment. The second case, a 45-year-old male patient, presented with severe abdominal pain and sudden obstruction of the gastrointestinal tract. Both patients had previous medical histories of malignant melanoma found on the skin of the subscapular area. The pathomorphological reports confirmed metastatic melanoma of the small bowel. The patients underwent partial resection of the small bowel with end-to-end anastomosis. Conclusion: Patients with metastatic melanoma originating from the small intestine had a poor prognosis. Due to the difficult diagnostic control of melanoma that develops on the skin and insufficient therapy for advanced stage cancer, we should develop early diagnostics for cutaneous melanoma through cancer prevention education in the population.
3

Serum beta-glucuronidase in colon cancer patients dependent on alcohol and nicotine: preliminary report

72%
Waszkiewicz N., Zalewska-Szajda B., Repka B., Szulc A., Kępka A., Chojnowska S., Dadan J., Ładny J., Zwierz K., Szajda S.
Progress in Health Sciences
|
2012
|
vol. 2
|
issue 2
64-69
EN
Introduction: Beta-glucuronidase (GLU) is a lysosomal exoglycosidase involved in the catabolism of glycoconjugates. Excessive GLU activity may be a primary factor in the etiology of colon cancer. The stimulation of glycosidases and other degradative enzyme activity has been noted in cancers as well as in alcohol and nicotine addiction. Purpose: To compare the serum GLU activity between alcohol- and nicotine-dependent colon cancer patients and colon cancer patients without a history of alcohol- and nicotine-dependence. Materials and methods: Material was the serum of 22 colon cancer patients, 11 of whom met alcohol and nicotine dependence criteria. The activity of serum GLU (pKat/ml) was determined by the colorimetric method. Carcinoembryonic antigen (CEA) concentration (ng/ml) in the serum was determined by the immunoenzymatic method. Comparisons between groups were made using the Mann-Whitney “U” test. Spearman’s rank correlation coefficient was used to measure the association between two variables. Results: The activity of serum GLU was significantly higher in colon cancer patients with a history of alcohol and nicotine dependence, than in the colon cancer patients without a history of drinking and smoking (p=0.003). There was no significant difference in the CEA concentration between colon cancer patients with and without a history of drinking and smoking. Conclusion: Alcohol and nicotine addiction may increase the serum GLU activity in all cancer patients, as already seen in colon cancer patients. This may potentially be important for the degradation of pericancerous matrix, tumor growth, invasion and metastasis
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.